A Phase 1, 2-Part, Open-label Study to Determine the Absorption, Metabolism, and Elimination of [14C]CC-90010 in Participants With Advanced Solid Tumors
Latest Information Update: 22 Apr 2024
At a glance
- Drugs Trotabresib (Primary)
- Indications Solid tumours
- Focus Pharmacokinetics
- Sponsors Bristol-Myers Squibb
- 16 Apr 2024 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 12 Jan 2023 New trial record